Elevated Prevalence of Abnormal Glucose Metabolism and Other Endocrine Disorders in Patients with β-Thalassemia Major: A Meta-Analysis

Biomed Res Int. 2019 Apr 18:2019:6573497. doi: 10.1155/2019/6573497. eCollection 2019.

Abstract

Background: Endocrinopathies are common in patients with β-thalassemia major despite parenteral iron chelation therapy with deferoxamine. Prevalence of abnormal glucose metabolism in previous studies was controversial. The aim of this study was to discuss the prevalence of abnormal glucose metabolism in β-thalassemia major based on a meta-analysis.

Methods: PubMed, ScienceDirect, Springerlink, Ovid, Web of Science, MEDLINE, Wanfang database, and Chinese National Knowledge Internet were searched for relevant articles. Two authors selected the articles according to the inclusion criteria and then extracted the data. The prevalence of diabetes mellitus (DM) in β-thalassemia major was defined as the primary outcome. The prevalence with the 95% confidence interval (95%CI) was used to evaluate the proportion of abnormal glucose metabolism and other endocrine disorders in patients with β-thalassemia major. Subgroup analyses were applied to explore the prevalence in different regions. Sensitivity analysis and publication bias assessment were also conducted.

Results: A total of 44 studies with 16605 cases were included in this analysis. Diabetes mellitus was present in 6.54% (95% CI: 5.30%-7.78%). The fixed subgroup study revealed that the region with the highest prevalence was the Middle East (prevalence= 7.90%, 95% CI: 5.75%-10.05%). The accumulated meta-analysis revealed that the prevalence of DM in β-thalassemia major was relatively steady in each year. The prevalence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and other endocrine disorders in β-thalassemia major was 17.21% (95% CI: 8.43%-26.00%), 12.46% (95% CI: 5.98%-18.94%), and 43.92% (95% CI: 37.94%-49.89%), respectively. Sensitivity analysis showed that the pooled results were robust; publication bias assessment revealed that there was no significant evidence that the pooled results were influenced by publication bias.

Conclusion: High prevalence of endocrine disorders involving abnormal glucose metabolism was detected in β-thalassemia major. Treatment and prevention measurements may be necessary to prevent growth and endocrine problems.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Chelation Therapy
  • Deferoxamine / therapeutic use
  • Diabetes Mellitus / epidemiology*
  • Diabetes Mellitus / metabolism
  • Diabetes Mellitus / pathology
  • Endocrine System Diseases / complications
  • Endocrine System Diseases / epidemiology*
  • Endocrine System Diseases / metabolism
  • Endocrine System Diseases / pathology
  • Glucose / metabolism*
  • Glucose Intolerance
  • Humans
  • Iron Chelating Agents / therapeutic use
  • Middle East / epidemiology
  • beta-Thalassemia / complications
  • beta-Thalassemia / epidemiology*
  • beta-Thalassemia / metabolism
  • beta-Thalassemia / pathology

Substances

  • Iron Chelating Agents
  • Glucose
  • Deferoxamine